Molecular pathways: preclinical models and clinical trials with metformin in breast cancer

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Metformin, an oral biguanide, is a common diabetes medication.
• It is being investigated for its potential anticancer properties.
• Both direct cellular actions and systemic effects are implicated in its antitumor potential.

Purpose of the Study:

• To review the evidence for metformin's role in cancer prevention and therapy.
• To explore the molecular mechanisms underlying metformin's anticancer effects.
• To assess the safety and efficacy of metformin in clinical trials for various cancers.

Main Methods:

• In vitro and preclinical studies examining cellular pathways (AMPK, mitochondrial ATP synthesis).
• Epidemiologic and retrospective clinical studies.
• Preoperative window-of-opportunity trials in breast cancer patients.
• Analysis of gene expression changes and insulin-mediated effects.

Main Results:

• Metformin demonstrates safety in preoperative breast cancer settings.
• It reduces tumor cell proliferation and alters gene expression.
• Insulin-mediated effects, independent of BMI, suggest therapeutic benefits.
• Clinical evidence supports metformin as an antitumor agent.

Conclusions:

• Metformin exhibits significant potential as an experimental cancer therapeutic.
• Further clinical trials are investigating its use in neoadjuvant, adjuvant, and advanced disease settings.
• Biomarker studies will refine patient selection for metformin-based cancer therapies.